Testicular cancer is rare. About 0.4 percent of men will be diagnosed with it at some point in their lives, which translates to roughly 1 in 250. In the United States, an estimated 9,810 new cases will be diagnosed in 2026, with about 630 deaths. To put that in perspective, prostate cancer alone accounts for nearly 300,000 new cases per year. Testicular cancer makes up a small fraction of all male cancers.
How the Numbers Break Down
That 0.4 percent lifetime risk means the vast majority of men will never develop testicular cancer. But “rare” doesn’t mean irrelevant, especially if you’re in the age group where it’s most common. Testicular cancer is the most frequently diagnosed cancer in men between roughly 15 and 35, even though its overall numbers are low. Outside that window, it becomes increasingly uncommon.
The estimated 630 annual deaths also tell an important story: testicular cancer has one of the highest cure rates of any cancer. Even when diagnosed at advanced stages, it responds well to treatment. That combination of low incidence and high survival is why public health agencies treat it differently from more common cancers.
Rates Are Rising, Not Falling
Despite being rare overall, testicular cancer has been getting more common over recent decades. Historically, non-Hispanic White men have had the highest rates. That’s shifting. Research from the National Cancer Institute shows that incidence among Hispanic men has risen to match White men for the first time, with Hispanic men seeing an average annual increase of about 3 percent. Hispanic men also tend to be diagnosed at a younger median age and are more likely to be diagnosed at advanced stages.
Meanwhile, rates among non-Hispanic White men have stabilized. The reasons behind these demographic shifts aren’t fully understood, but the trend means the cancer’s rarity shouldn’t breed complacency, particularly for younger men.
Who Faces Higher Risk
Certain factors push your individual risk above that 1-in-250 baseline. The most significant is cryptorchidism, a condition where one or both testicles don’t descend into the scrotum before birth. Men born with undescended testicles are many times more likely to develop testicular cancer than men whose testicles descended normally, even if the condition was surgically corrected in childhood.
Other factors that raise risk include having a family history of testicular cancer (particularly a brother or father who had it), a personal history of cancer in one testicle, and certain differences in sexual development. Being tall is also weakly associated with higher risk, though the connection isn’t strong enough to be clinically useful. None of these factors make testicular cancer likely for any individual, but they do shift the odds.
Why Routine Screening Isn’t Recommended
Given how rare testicular cancer is and how treatable it remains even at later stages, the U.S. Preventive Services Task Force actually recommends against routine screening in men who have no symptoms. That includes both self-exams and clinical exams by a doctor. The task force’s reasoning is straightforward: the cancer is so uncommon and so curable that screening an asymptomatic population creates more harm than benefit. False positives lead to unnecessary anxiety, imaging, and sometimes biopsies in men who turn out to be fine.
This doesn’t mean you should ignore changes in your body. A painless lump or swelling in a testicle, a feeling of heaviness in the scrotum, or a dull ache in the lower abdomen or groin are all worth mentioning to a doctor. The distinction is between a systematic screening program (not helpful here) and paying attention to something that feels different (always reasonable). Most men who notice a lump won’t have cancer, but the ones who do benefit enormously from early evaluation.
Survival Rates Are Exceptionally High
Part of what makes testicular cancer unusual among cancers is its prognosis. The overall five-year survival rate is above 95 percent. When caught while still confined to the testicle, survival approaches 99 percent. Even when the cancer has spread to distant parts of the body, the majority of men survive, thanks to the cancer’s strong responsiveness to treatment. That 630-death estimate against nearly 10,000 new cases reflects just how effective modern treatment is.
This high cure rate is precisely why the medical community doesn’t panic about testicular cancer the way it does about lung or pancreatic cancer. It’s rare, it’s treatable, and most men diagnosed with it go on to live normal lifespans. The practical takeaway: testicular cancer is uncommon enough that worrying about it serves no purpose, but being aware of what your body normally feels like means you’ll notice if something changes.